| Similar Articles |
|---|
 |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet.   |
The Motley Fool
November 1, 2010
Brian Orelli |
Stock Doubles! No Crying Here AVANIR Pharmaceuticals' investors didn't have any uncontrolled crying on Friday when the Food and Drug Administration approved Nuedexta, the company's treatment for pseudobulbar affect. |
The Motley Fool
February 29, 2008
Brian Lawler |
Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease. |
The Motley Fool
November 25, 2011
Brian Orelli |
7 Black Friday Biotech Bargains Get in at the right time to maximize your returns. |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
Chemistry World
December 4, 2014
Phillip Broadwith |
Otsuka to buy neurology specialist Avanir Japanese firm Otsuka has agreed to buy US neurological drug specialist Avanir for $3.5 billion in cash. |
The Motley Fool
December 29, 2011
Brian Orelli |
Too Early for a New Biotech Orphan? Alexion Pharmaceuticals is profitable with a drug on the market. The next logical step in the progression of a biotech is to buy another company to stock the pipeline. |
Pharmaceutical Executive
September 1, 2008
Jeffrey S. Aronin |
The Orphan Opportunity The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
American Family Physician
December 15, 2006 |
Parkinson's Disease: What You Should Know What is Parkinson's disease?... How can I tell if I have Parkinson's disease?... How will my doctor know if I have it?... How is Parkinson's disease treated?... etc. |
The Motley Fool
May 1, 2008
Brian Lawler |
Soliris Brightens Alexion's Quarter Alexion Pharmaceuticals' lone drug posts gargantuan growth. |
The Motley Fool
March 25, 2011
Selena Maranjian |
Make Money in Pharmaceuticals the Easy Way There's no need to guess which pharmaceutical company will perform best with the SPDR S&P Pharmaceuticals ETF. |
The Motley Fool
July 21, 2011
Tim Beyers |
Alexion Pharmaceuticals Shares Popped: What You Need to Know Shares of Alexion Pharmaceuticals rose close to 11% in early trading and touched a new 52-week high of $57.73 a share after the biotech company raised its full-year forecast. |
The Motley Fool
January 31, 2011
Dan Dzombak |
5 Small-Cap Stocks on Fire These five watchlist stocks have been on fire lately: Capstone Turbine... Avanir Pharmaceuticals... Power-One... Oilsands Quest... FuelCell Energy... |
The Motley Fool
February 1, 2008
Brian Lawler |
Alexion Looks for a Bigger Niche Alexion Pharmaceutical announces sales of its rare blood disorder medication should expand in 2008. |
The Motley Fool
November 28, 2011
David Williamson |
5 Biotechs Posting Big Gains The daily health-care news investors need to read. |
The Motley Fool
February 27, 2007
Brian Lawler |
Mostly Good From BioMarin Drugmaker BioMarin updates investors on its drug pipeline and quarterly financial results. |
Managed Care
March 2000
Steve Heimoff |
Getting Out From Under Drug Companies' Shadows The perception that disease management is merely a drug marketing tool seems finally to have vanished from this healthy, though fragmented, industry. |
The Motley Fool
December 13, 2011
David Williamson |
3 Biotechs Making Big Moves on Big News Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
July 23, 2011 |
Regeneron Pharmaceuticals Earnings Preview Regeneron Pharmaceuticals will unveil its latest earnings on Wednesday, July 27. |
The Motley Fool
April 30, 2007
Brian Lawler |
Alexion Heads Overseas Alexion is headed for approval of its lead compound in the European Union. With no other compounds in clinical stage development, an investment in Alexion is all about the market potential for Soliris. |
The Motley Fool
April 1, 2008
Brian Lawler |
BioMarin Drug Heads Overseas One of the pharmaceutical's enzyme replacement therapy drugs gets approved in Japan. |
